| Autor: |
Gupta SL; National Institute of Immunology, New Delhi 110067, India., Tyagi R; College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China., Dhar A; National Institute of Immunology, New Delhi 110067, India., Oswal N; National Institute of Immunology, New Delhi 110067, India., Khandelwal A; Jhalawar Medical College, Jhalawar 326001, India., Jaiswal RK; Department of Cancer Biology, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA. |
| Abstrakt: |
SARS-CoV-2, a novel coronavirus, causes respiratory tract infections and other complications in affected individuals, and has resulted in numerous deaths worldwide. The unprecedented pace of its transmission worldwide, and the resultant heavy burden on healthcare systems everywhere, prompted efforts to have effective therapeutic strategies and vaccination candidates available to the global population. While aged and immunocompromised individuals form a high-risk group for COVID-19 and have severe disease outcome, the rate of infections among children has also increased with the emergence of the Omicron variant. In addition, recent reports of threatening SARS-CoV-2-associated complications in children have brought to the forefront an urgent necessity for vaccination. In this article, we discuss the current scenario of SARS-CoV-2 infections in children with a special focus on the differences in their immune system response as compared to adults. Further, we describe the various available COVID-19 vaccines, including the recent bivalent vaccines for children, in detail, intending to increase willingness for their acceptance. |
